Actinium Pharmaceuticals (ATNM) Received its Third Buy in a Row


After H.C. Wainwright and William Blair gave Actinium Pharmaceuticals (NYSE MKT: ATNM) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy reiterated a Buy rating on Actinium Pharmaceuticals yesterday and set a price target of $25.00. The company’s shares closed last Wednesday at $8.38.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 28.2% and a 46.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Interpace Diagnostics Group.

Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $38.75, implying a 354.8% upside from current levels. In a report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $40.00 price target.

See today’s analyst top recommended stocks >>

Actinium Pharmaceuticals’ market cap is currently $109.8M and has a P/E ratio of -4.20. The company has a Price to Book ratio of 3.21.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts